Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,170
  • Shares Outstanding, K 128,434
  • Annual Sales, $ 650 K
  • Annual Income, $ -49,500 K
  • 60-Month Beta 0.50
  • Price/Sales 66.75
  • Price/Cash Flow N/A
  • Price/Book 3.32
Trade CLNN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings $-0.06 on 03/13/24
  • Latest Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 223.18% ( -28.23%)
  • Historical Volatility 86.68%
  • IV Percentile 40%
  • IV Rank 16.30%
  • IV High 1,068.19% on 04/24/24
  • IV Low 58.66% on 01/17/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 229
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 9,770
  • Open Int (30-Day) 9,370

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3040 +42.04%
on 04/16/24
0.4600 -6.13%
on 04/04/24
+0.0064 (+1.50%)
since 03/28/24
3-Month
0.3040 +42.04%
on 04/16/24
0.5326 -18.93%
on 01/31/24
-0.0881 (-16.95%)
since 01/30/24
52-Week
0.2500 +72.72%
on 12/27/23
1.0900 -60.39%
on 06/15/23
-0.5182 (-54.55%)
since 04/28/23

Most Recent Stories

More News
Clene (NASDAQ: CLNN) Continues Development of CNM Au8(R) for Neurodegenerative Diseases

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as MS Treatment Presented at AAN Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”)...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R)

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function....

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat...

CLNN : 0.4318 (+22.78%)
Clene’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN) Announces Participation at 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference...

CLNN : 0.4318 (+22.78%)
Clene (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational...

CLNN : 0.4318 (+22.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 0.3720
2nd Resistance Point 0.3632
1st Resistance Point 0.3575
Last Price 0.4318
1st Support Level 0.3430
2nd Support Level 0.3342
3rd Support Level 0.3285

See More

52-Week High 1.0900
Fibonacci 61.8% 0.7691
Fibonacci 50% 0.6700
Fibonacci 38.2% 0.5709
Last Price 0.4318
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar